
jul pm et
summari compani provid diagnost test inform servic physician hospit
manag care organ employ govern agenc
price-to-earnings oper ep
risk assess reflect leadership posit
larg matur diagnost test industri
compani broad geograph servic area divers
balanc custom mix grow recognit
import signific diagnost test
think regulatori uncertainti creat risk
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
look sale growth
respect see flat
organ volum growth recent
growth driven small acquisit
jun receiv day dso
increas six day year-over-year day
higher level quarter past
three year think could suggest
futur revenu pressur attribut
increas signific laboratori convers
posit side expect
profession laboratori servic deal
also may announc
form long-term strateg partnership
unitedhealthcar one
largest health care insur
begin network
plan particip like lead
increas end-us demand
see gross margin
compar
ebit margin
compar see
benefit recent cost cut effort
shift higher margin test complet
off-set reimburs pressur
ep estim
think share
ep estim
trade fair valu revenu
grow slow pace five-year
cumul annual growth rate compound-annual-growth-rate
year end see continu
loss market share competitor
clinic lab fee schedul clf
center medicar medicaid servic
publish reimburs rate
clinic laboratori test result substanti
rate cut protect
access medicar act pama test price
cut maximum
revenu reduc
risk recommend target price
includ better-than-expect accret
acquisit higher-than-expect
target price
ep estim discount
peer given below-averag earn
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview largest independ clinic lab oper clinic
lab market estim billion market hospital-bas lab account
market independ commerci lab account physician-offic
lab rest offer broad rang clinic laboratori test servic use physician
detect diagnosi treatment diseas medic condit test rang routin
blood cholesterol test highli complex esoter gene-bas test molecular
diagnost test end network princip laboratori throughout
number smaller rapid respons stat laboratori patient servic center along
facil mexico puerto rico england start provid clinic lab servic india
test gener net sale gene-bas esoter anatom patholog test
clinic trial risk assess servic labon acquir novemb healthcar
routin test measur import health paramet function kidney heart liver
thyroid organ esoter test perform less frequent routin test and/or requir
sophist equip materi profession hands-on attent highli skill
personnel result gener price substanti higher routin test
corpor strategi largest compani see matur market limit growth
potenti forese annual industri sale growth mid-singl digit gener sale
industri averag embark multi-prong strategi call patient growth peopl
strategi focus provid high-qual servic offer broadest access distribut
think aid attract retain custom growth deriv organ
acquisit clinic lab industri highli fragment sever thousand clinic lab
acquisit bought sever dozen lab past decad although think
limit number sizabl acquisit candid remain expect remain acquisit
recent sizabl transact includ march acquisit celera corpor april
acquisit athena diagnost may acquisit ameripath februari acquisit
unilab novemb acquisit labon complet one acquisit
million complet five acquisit total consider million organ
growth achiev opinion increas number higher-pr esoter test offer
price hike rais number test per requisit last part strategi attract
retain talent motiv work forc
competit landscap clinic lab industri highli competit thousand independ
clinic lab physician offic lab hospital-bas lab largest provid lab servic
thu enjoy leverag competitor main competitor publicli trade laboratori
corpor america significantli smaller competitor includ bio-refer laboratori
financi trend sale increas billion billion repres
compound annual growth rate compound-annual-growth-rate impact declin physician offic visit lower
reimburs rate oper margin fluctuat past sever year rang
adjust ep increas ep growth
aid activ stock repurchas program note debt level increas
substanti ameripath acquisit along recent deal total long-term debt
decemb billion
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
bullish sinc may technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
base index
five-year market price perform jul
success elimin individu
mandat passag tax cut
job act decemb see
develop neg health care
servic provid fewer custom like
enrol insur plan start
fewer patient insur uncompens
care rate could rise hospit
facil lead lower profit
lower demand supplement health care
year date june
versu increas
composit index health
servic increas vs
increas composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
fundament outlook health care
servic sub-industri next month
neutral think servic includ
rehabilit clinic laboratori
dialysi continu benefit
trend continu pressur
trump administr reduc govern
spend turn rais
possibl medicar reimburs rate
cut repeal afford act
rollback medicaid expans
expect provid servic dialysi
rehabilit center see mix
util increas drug price
servic provid must maintain commerci
custom base uphold profit level
custom pay higher rate
medicar
think age popul
increas focu prevent care
benefit clinic lab addit expect
increas number test per
requisit esoter test could lead
low-single-digit sale growth lab
lower outlook pharmaci benefit
manag pbm posit neutral
see lower level drug price inflat hurt
growth still high util
also see pbm continu benefit
mani brand drug lost patent
protect recent year increas
gener drug usag would increas
profit pbm
although republican administr
 difficulti repeal
stop medicaid expans think
repeal question
senat fail multipl time gather
suffici number vote pass variou
repeal replac bill howev republican
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
consensu sale increas volum growth growth
revenu per requisit see sale growth driven mostli
diagnost inc center medicar medicaid
servic publish propos medicar reimburs rate
clinic laboratori test clinic lab fee schedul clf
accord propos payment lab test would decreas
major test code receiv maximum reduct issu
statement call method use calcul price
flaw see neg given modest
exposur medicar reimburs note compani like challeng
propos rate court /keith snyder
diagnost inc keep target
ep estim discount peer slight premium
forward averag price-to-earnings reflect improv
below-p sale growth expect rais ep
estim report oper
ep vs consensu sale increas
volum growth revenu per requisit growth expect
sale growth aid acquisit volum growth partial
off-set modest price pressur /k snyder
diagnost inc rais target
ep estim multipl line
three-year forward averag price-to-earnings reflect stabl revenu growth outlook
increas ep estim keep
report oper ep vs
consensu aid tax benefit associ
share-bas compens sale increas report basi driven
volum growth see sale growth aid
acquisit stabl price addit volum growth /k snyder
analyst research note compani news
et cfra reiter sell opinion share quest
diagnost incorpor rais target
below-p ep estim
multipl reflect expect slow sale growth margin
deterior ep vs lower
estim sale increas billion requisit volum
grew quarter driven acquisit revenu per
requisit grew basi point vs prior-year period
oper margin compar
neg impact invest use tax reform save acquisit
still earli stage integr price reduct result
protect access medicar act pama receiv day dso
increas six day yoy day higher level quarter
past three year think could suggest futur revenu pressur
attribut increas signific laboratori convers /kevin huang
diagnost incorpor share trade midday
news format long-term strateg partnership
unitedhealthcar one largest health care insur
 begin network plan particip
includ million enrol peopl time renew
exist long-term strateg partnership labcorp lh
result lh longer unh exclus nation laboratori
provid see posit compani like see
increas end-us demand howev develop may
suffici counteract underli challeng face /kevin
diagnost incorpor keep target price
ep estim slight discount peer reflect
slow sale growth outlook rais ep estim
report oper ep vs
consensu sale increas driven growth
diagnost inform servic volum grew driven almost entir
acquisit offset weather impact revenu per requisit
grew ebit margin fell impact lower reimburs
rate pama weather disrupt acquisit still
earli stage integr expect ebit margin recov
end year integr recent acquisit progress see
sale growth previou estim growth
impact flat organ growth addit reimburs pressur /keith
diagnost keep target price
ep estim slight discount ten-year forward
averag price-to-earnings reflect slow sale growth outlook risk
stem regulatori uncertainti rais ep estim
set report oper
ep vs consensu sale increas
volum growth increas revenu per requisit see
sale growth driven mostli acquisit partli off-set
diagnost keep target price
ep estim multipl line five-year
forward averag price-to-earnings balanc slow organ sale growth outlook
expect modest margin expans driven effici improv effort
trim ep estim
report oper ep vs
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
